At the Keystone Symposia Conference, Infinity Pharmaceuticals Inc. (NASDAQ:INFI) showcased preclinical report for IPI-549. The drug is able to aid overcome conflict to checkpoint inhibition by altering the immune-suppressive tumor microenvironment mainly through its impacts on myeloid cells. It is a cell type considered to be involved in subduing immune response against tumors.
Preliminary Phase 1 monotherapy data from 9 subjects with advanced solid tumors were summarized and demonstrated that the safety, pharmacodynamics and pharmacokinetics of IPI-549 monotherapy therapy seemed favorable. IPI-549 is considered to be the sole PI3K-gamma inhibitor in drug’s clinical development.
Infinity Pharmaceuticals preclinical report offers a compelling rationale for company’s ongoing Phase I clinical trial designed to assess IPI-549 as a monotherapy and also in combination with Opdivo®, in subjects with advanced solid tumors. The combined therapy portion of the Phase I trial will comprise subjects with non-small cell lung cancer, melanoma, and SCCHN whose tumors demonstrated initial resistance or subsequently advance resistance to immune checkpoint treatment. There is a great requirement for additional treatment alternatives for the increasing number of subjects residing with these cancers, which comprise over 17% of all new cancer cases in the United States.
While new immunotherapies are showing immense promise in the cure of different cancers, there are numerous mechanisms of immune tolerance in cancer tumors. Additional treatment alternatives are required for patients who relapse or fail to respond to currently available treatments. The data presented indicate that targeting PI3K-gamma by ‘IPI-549’ could provide an innovative way to both improve the activity of checkpoint inhibition in certain sensitive tumors, and to deal with tumor resistance to spot check inhibition.
Infinity is thrilled to be at the forefront of advancing a potentially transformative mechanism within immuno-oncology, and it anticipates reporting additional data from Phase 1 trial of ‘IPI-549’ later this year.